

Antonio Jose Sanchez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1037813/publications.pdf>

Version: 2024-02-01

40
papers

1,349
citations

394421

19
h-index

345221

36
g-index

43
all docs

43
docs citations

43
times ranked

2291
citing authors

#	ARTICLE	IF	CITATIONS
1	A sustained activation of PI3K/NF- κ B pathway is critical for the survival of chronic lymphocytic leukemia B cells. <i>Leukemia</i> , 2004, 18, 1391-1400.	7.2	233
2	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015, 138, 918-931.	7.6	147
3	Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. <i>Neurobiology of Disease</i> , 2005, 20, 207-217.	4.4	131
4	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	7.6	115
5	Neuroprotective agents: Cannabinoids. <i>Clinical Immunology</i> , 2012, 142, 57-67.	3.2	95
6	Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. <i>Synapse</i> , 2001, 41, 195-202.	1.2	62
7	Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. <i>Oncoscience</i> , 2015, 2, 131-141.	2.2	57
8	R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: Partial involvement of the CB2 receptor. <i>Biochemical Pharmacology</i> , 2006, 72, 1697-1706.	4.4	53
9	Multiple sclerosis associates with LILRA3 deletion in Spanish patients. <i>Genes and Immunity</i> , 2009, 10, 579-585.	4.1	42
10	Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon- γ : a longitudinal study in multiple sclerosis patients. <i>Clinical and Experimental Immunology</i> , 2014, 179, 119-127.	2.6	38
11	Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. <i>PLoS ONE</i> , 2022, 17, e0263140.	2.5	38
12	Selective Induction of cAMP Phosphodiesterase PDE4B2 Expression in Experimental Autoimmune Encephalomyelitis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 923-931.	1.7	32
13	Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study. <i>Frontiers in Immunology</i> , 2018, 9, 1693.	4.8	32
14	Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis. <i>Experimental Neurology</i> , 2017, 298, 57-67.	4.1	28
15	Rolipram impairs NF- κ B activity and MMP-9 expression in experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2005, 168, 13-20.	2.3	27
16	Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin Treatment. <i>PLoS ONE</i> , 2016, 11, e0161954.	2.5	26
17	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. <i>Journal of Neuroinflammation</i> , 2018, 15, 265.	7.2	25
18	The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. <i>Multiple Sclerosis Journal</i> , 2010, 16, 139-146.	3.0	25

#	ARTICLE	IF	CITATIONS
19	Pharmacogenomic study in patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e154.	6.0	19
20	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 239, 101-104.	2.3	18
21	CSF Chitinase 3- β -Glucosaminidase 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	15
22	Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 1243-1250.	2.8	13
23	Serum endocannabinoid levels in suicide attempters: A pilot study. <i>European Neuropsychopharmacology</i> , 2020, 40, 52-60.	0.7	12
24	Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review. <i>Current Psychiatry Reports</i> , 2018, 20, 19.	4.5	11
25	Metabolic syndrome contributes to renal injury mediated by hyperoxaluria in a murine model of nephrolithiasis. <i>Urolithiasis</i> , 2018, 46, 179-186.	2.0	9
26	Los estudiantes con discapacidad en la Universidad de Almería: Ideas y Actitudes sobre su integración Educativa y Social. <i>European Journal of Education and Psychology</i> , 2010, 3, 329.	1.5	9
27	Nox1-derived oxidative stress as a common pathogenic link between obesity and hyperoxaluria-related kidney injury. <i>Urolithiasis</i> , 2020, 48, 481-492.	2.0	6
28	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0134414.	2.5	5
29	ISNI 2010 Abstracts. <i>Journal of Neuroimmunology</i> , 2010, 228, 1-219.	2.3	4
30	Serum β -endorphin levels are associated with addiction to suicidal behavior: A pilot study. <i>European Neuropsychopharmacology</i> , 2020, 40, 38-51.	0.7	4
31	Effect of Expanded Hemodialysis with Theranova [®] in Patients with COVID-19. <i>Blood Purification</i> , 2022, 51, 857-865.	1.8	2
32	Therapeutic potential of human mesenchymal cells from Multiple Sclerosis patients in EAE. <i>Journal of Neuroimmunology</i> , 2014, 275, 190.	2.3	1
33	Exploring the potential relationship between collagen cross-linking and impaired myocardial relaxation in Marfan syndrome: An observational study using serum biomarkers. <i>International Journal of Cardiology</i> , 2022, , .	1.7	1
34	Esclerosis múltiple. Factores etiológicos, modelos experimentales, mecanismos patogénicos e inmunopatología. <i>Medicine</i> , 2011, 10, 5069-5078.	0.0	0
35	Manifestaciones clínicas, historia natural, pronóstico y complicaciones de la esclerosis múltiple. <i>Medicine</i> , 2011, 10, 5079-5086.	0.0	0
36	Tratamiento de la esclerosis múltiple. <i>Medicine</i> , 2011, 10, 5094-5100.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Otras enfermedades desmielinizantes. <i>Medicine</i> , 2011, 10, 5101-5107.	0.0	0
38	Protocolo diagnóstico del paciente con sospecha de enfermedad desmielinizante. <i>Medicine</i> , 2011, 10, 5109-5111.	0.0	0
39	Protocolo terapéutico de la esclerosis múltiple. <i>Medicine</i> , 2011, 10, 5112-5113.	0.0	0
40	The cannabinoid system in human mesenchymal cells. <i>Journal of Neuroimmunology</i> , 2014, 275, 189-190.	2.3	0